TabletsTablets
Schedule H1 (Prescription Required - Habit Forming Warning)Antiepileptics & AnticonvulsantsCode: 1110

Clobazam Tablet 5mg

Generic Formulation:Clobazam Tablet IP 5mg
Pack Size:10's
Common Commercial Brand Equivalents:Market reference only
Jan Aushadhi MRP
₹15.47
Brand Estimate*
₹88.46
Estimated Savings:₹72.99 (83% saved)
Find a Kendra Near You
*Statutory price across 21,118 listed Kendras
Clinical InformationReport Error

Clinical Overview

Clobazam is a 1,5-benzodiazepine with preferential affinity for the alpha-2 subunit of GABAA receptors over alpha-1, conferring potent anticonvulsant and anxiolytic efficacy with reduced sedative and motor impairment compared to traditional 1,4-benzodiazepines. Its active metabolite, N-desmethylclobazam, provides prolonged neuronal stabilization. Indicated as adjunctive therapy for refractory epilepsy, Lennox-Gastaut syndrome, and severe anxiety.

Active Pharmaceutical Ingredients

AI-assistedClinical summary synthesized from pharmacopoeial references (CDSCO, WHO EML, IP/BP/USP). Not clinician-reviewed. Drug code 1110.Report inaccuracy

Usage Guidelines

Take orally with water, with or without food. Tablets can be swallowed whole or crushed and mixed with applesauce. Doses should be titrated gradually and tapered slowly before stopping.

General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.

Possible Side Effects

Common: Somnolence, sedation, fever, lethargy, drooling, constipation, aggression. Rare/Severe: Boxed warning: Serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), respiratory depression, physical dependence, and suicidal ideation.

*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.

Precautions & Warnings

Black box warning: Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis, especially in the first 8 weeks of therapy; seek emergency medical care at the first sign of rash. Boxed warning for dependence and abuse. Dose adjustment required in CYP2C19 poor metabolizers.

Schedule H1 (Prescription Required - Habit Forming Warning)

This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.

Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified pharmacist before initiating, modifying, or substituting any medication regimen.